Comparative Levels of Urinary Prostate‑specific Antigen and Microseminoprotein‑beta in Men with and without Prostate Cancer
Authors/Creators
- 1. Assistant Professor, Department of Urology, GRMC, Gwalior, M.P.
- 2. Assistant Professor, Department of Community Medicine, GRMC, Gwalior, M.P.
- 3. Associate Professor, Department of Physiology, GMC, Dholpur, Rajasthan
- 4. Associate Professor, Department of Community Medicine, GMC, Datia, M.P.
Description
Introduction: The role of urinary proteomics in the diagnosis of prostate cancer (PCa) is undefined. Levels of urinary biomarkers such as prostate‑specific antigen (PSA) and microseminoprotein‑beta (MSMB) may differ between men with and without PCa. Objective: We tested this hypothesis using urine samples before and after digital rectal examination (DRE) in men with an indication for prostate biopsy. Materials and Methods: This prospective cohort study was done in Department of Urology, GRMC, Gwalior and approved by the institutional ethics committee and all individuals provided informed consent for inclusion. Men scheduled to undergo transrectal ultrasound (TRUS)‑guided biopsy of the prostate for suspicion of PCa due to either elevated PSA (>4 ng/mL) or a nodule on DRE were recruited. A sterile urine culture was confirmed before inclusion. Results: Seventy‑seven patients were recruited of whom 32 had PCa (Group A) and 45 had no cancer (Group B) on biopsy. The median (interquartile range) serum PSA was 49.6 (0.2–254) ng/ml. The median urine PSA (29.5 vs. 26.4 mg/dl) and MSMB (1.7 vs. 2.4 mg/dl) were similar in both groups at baseline. However, post‑DRE, both these metabolites rose in Group B but not in Group A, resulting in significantly higher post‑to‑pre values in Group B versus Group A. The post‑DRE urine PSA/MSMB ratio was also significantly different between the groups. Conclusions: Urinary PSA and MSMB rose significantly after DRE only in men without PCa. Post‑DRE urine PSA, MSMB, and PSA/MSMB ratio can differentiate PCa from benign pathology in men with an indication for prostate biopsy.
Abstract (English)
Introduction: The role of urinary proteomics in the diagnosis of prostate cancer (PCa) is undefined. Levels of urinary biomarkers such as prostate‑specific antigen (PSA) and microseminoprotein‑beta (MSMB) may differ between men with and without PCa. Objective: We tested this hypothesis using urine samples before and after digital rectal examination (DRE) in men with an indication for prostate biopsy. Materials and Methods: This prospective cohort study was done in Department of Urology, GRMC, Gwalior and approved by the institutional ethics committee and all individuals provided informed consent for inclusion. Men scheduled to undergo transrectal ultrasound (TRUS)‑guided biopsy of the prostate for suspicion of PCa due to either elevated PSA (>4 ng/mL) or a nodule on DRE were recruited. A sterile urine culture was confirmed before inclusion. Results: Seventy‑seven patients were recruited of whom 32 had PCa (Group A) and 45 had no cancer (Group B) on biopsy. The median (interquartile range) serum PSA was 49.6 (0.2–254) ng/ml. The median urine PSA (29.5 vs. 26.4 mg/dl) and MSMB (1.7 vs. 2.4 mg/dl) were similar in both groups at baseline. However, post‑DRE, both these metabolites rose in Group B but not in Group A, resulting in significantly higher post‑to‑pre values in Group B versus Group A. The post‑DRE urine PSA/MSMB ratio was also significantly different between the groups. Conclusions: Urinary PSA and MSMB rose significantly after DRE only in men without PCa. Post‑DRE urine PSA, MSMB, and PSA/MSMB ratio can differentiate PCa from benign pathology in men with an indication for prostate biopsy.
Files
IJTPR,Vol13,Issue5,Article36.pdf
Files
(398.3 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:94a0cc9a6f5505b546d30ed668b73189
|
398.3 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-05-25
Software
References
- 1. Roethke MC, Kuru TH, Schultze S, Tichy D, Kopp‑Schneider A, Fenchel M, et al. Evaluation of the ESUR PI‑RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion‑guided biopsy at 3.0 Tesla. Eur Radiol 2014;24:344‑52. 2. You J, Cozzi P, Walsh B, Willcox M, Kearsley J, Russell P, et al. Innovative biomarkers for prostate cancer early diagnosis and progression. Crit Rev Oncol Hematol 2010;73:10‑22. 3. Ploussard G, de la Taille A. Urine biomarkers in prostate cancer. Nat Rev Urol 2010;7:101‑9. 4. Duijvesz D, Luider T, Bangma CH, Jenster G. Exosomes as biomarker treasure chests for prostate cancer. Eur Urol 2011;59:823‑31. 5. Shui IM, Lindström S, Kibel AS, Berndt SI, Campa D, Gerke T, et al. Prostate cancer (PCa) risk variants and risk of fatal PCa in the national cancer institute breast and prostate cancer cohort consortium. Eur Urol 2014;65:1069‑75. 6. Mhatre DR, Mahale SD, Khatkhatay MI, Achrekar SK, Desai SS, jagtap DD, et al. The rs10993994 in the proximal MSMB promoter region is a functional polymorphism in Asian Indian subjects. Springerplus 2015;4:380. 7. Peng T, Zhang L, Zhu L, Mi YY. MSMB gene rs10993994 polymorphism increases the risk of prostate cancer. Oncotarget 2017;8:28494‑501. 8. Graves HC, Sensabaugh GF, Blake ET. Postcoital detection of a male‑specific semen protein. Application to the investigation of rape. N Engl J Med 1985;312:338‑43. 9. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, et al. American Joint Committee on Cancer Staging Manual. 7th ed. New York: Springer; 2010. 10. Drake RR, White KY, Fuller TW, Igwe E, Clements MA, Nyalwidhe JO, et al. Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. J Proteomics 2009;72:907‑17. 11. Chybowski FM, Bergstralh EJ, Oesterling JE. The effect of digital rectal examination on the serum prostate specific antigen concentration: Results of a randomized study. J Urol 1992;148:83‑6. 12. Coleen MA, Thomas JD, David SM, Anthony PP, Lana T, Jill W, et al. Effect of digital rectal examination on serum prostate‑specific antigen in a primary care setting. The internal medicine clinic research consortium. Arch Intern Med 1995;155:389. 13. Bolduc S, Lacombe L, Naud A, Grégoire M, Fradet Y, Tremblay RR. Urinary PSA: A potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. Can Urol Assoc J 2007;1:377‑81. 14. Iwakiri J, Granbois K, Wehner N, Graves HC, Stamey T. An analysis of urinary prostate specific antigen before and after radical prostatectomy: Evidence for secretion of prostate specific antigen by the periurethral glands. J Urol 1993;149:783‑6. 15. Walter s KM, Stram DO, Le Ma rchand L , Klein RJ , Valtonen‑Andre C, Peltola MT, et al. A common prostate cancer risk variant 5' of microseminoprotein‑beta (MSMB) is a strong predictor of circulating beta‑microseminoprotein (MSP) levels in multiple populations. Cancer Epidemiol Biomarkers Prev 2010;19:2639‑46